Indo US Bio-Tech Limited reported a net profit of ₹3.04 crore for the quarter ended June 30, 2026, a 35% increase from ₹4.70 crore in the corresponding quarter of FY26. Revenue from operations grew 7% year-on-year to ₹32.99 crore, driven by steady demand in its seed cultivation, processing, and trading segment. The improvement in profitability was primarily aided by a significant reduction in employee benefit expenses, which turned negative in the prior year due to reversals, stabilizing operational costs in the current period.

The Board of Directors, at a meeting held on August 12, 2026, approved the unaudited standalone financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and received a limited review report from Bhagat & Associates, the statutory auditors, who expressed an unmodified opinion on the financial statements.

Financial Performance Highlights

*Note: Total expenses calculation includes Purchase of stock (₹524.19 lakh), Production Expenses (₹862.55 lakh), Employee Benefits (₹1,215.96 lakh), Finance Costs (₹32.94 lakh), Depreciation (₹73.93 lakh), and Other Expenses (₹26.89 lakh). The source table lists "Total Expenses" as ₹266.90 lakh before a subsequent line item of ₹3,003.35 lakh, which aligns with the sum of individual expense categories minus the negative impact of inventory changes or specific accounting adjustments not explicitly detailed in the summary rows. The profit before tax is derived as Total Income (₹3,311.05 lakh) less Total Expenses (₹3,003.35 lakh).

Revenue from operations stood at ₹3,298.68 lakh, compared to ₹3,076.96 lakh in Q1FY26. Other income increased significantly to ₹12.38 lakh from ₹0.15 lakh in the prior year. Production expenses rose to ₹862.55 lakh from ₹883.95 lakh in the same quarter last year, indicating stable cost management in core activities. However, employee benefit expenses recorded at ₹1,215.96 lakh contrasted with a credit of ₹(1,907.58) lakh in Q1FY26, reflecting a normalization of costs after prior-period adjustments.

What the Numbers Show

The divergence between revenue growth and profit decline highlights the impact of one-time items in the previous year. While revenue expanded by 7%, the profit before tax fell 36% because Q1FY26 benefited from a substantial reversal in employee benefits (₹1,907.58 lakh credit), whereas Q1FY27 incurred standard charges of ₹1,215.96 lakh. Excluding this anomaly, the underlying operational structure remains consistent, with production costs remaining relatively flat against higher sales volumes. The company continues to operate in a single major segment: Seed Cultivation, Processing & Trading.

The Board meeting commenced at 14:30 and concluded at 15:10 on August 12, 2026. There were no investor complaints pending or received during the period under review. The financial results have been prepared in accordance with Ind-AS 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013.

Indo Us Bio-Tech Limited shareholders have approved the regularization of Hemanshi Darsh Soni as a non-executive independent director and the appointment of M/s. Bhagat & Associates as statutory auditor, following a remote e-voting postal ballot process. The voting period ran from July 5, 2026, to August 3, 2026, with results declared on August 5, 2026. Both resolutions secured overwhelming support, with 100% of polled votes cast in favor, signaling clear shareholder endorsement of the company’s governance appointments.

The postal ballot was conducted in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Sections 108 and 110 of the Companies Act, 2013. Amrish Gandhi & Associates served as the scrutinizer for the process, overseeing the remote e-voting facility provided by National Securities Depository Limited (NSDL). The cut-off date for determining voting eligibility was June 26, 2026, with 4,774 shareholders eligible to vote on a total equity shareholding of 2,00,52,000 shares.

Voting Results Breakdown

The promoter group held 1,36,93,643 shares (68.29% of total equity) and voted entirely in favor of both resolutions. Public non-institutional shareholders, holding 63,58,357 shares, participated actively, polling 2,94,924 votes (4.64% participation rate). Of these, 2,94,919 votes were cast in favor, while only five votes were recorded against each resolution. No public institutional shareholders held stakes or participated in the vote.

Governance Implications

The regularization of Hemanshi Darsh Soni (DIN: 11659183) addresses prior procedural gaps in her initial appointment as an additional director. Her confirmation strengthens the board’s independent oversight capacity, a key metric for regulatory compliance and investor confidence. Meanwhile, the appointment of Bhagat & Associates (FRN: 101100W) as statutory auditor ensures continuity in financial reporting integrity, particularly relevant given the company’s ISO-certified operations and DSIR-recognized R&D unit.

Pursuant to Regulations 59 and Schedule XX of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, three shareholders voted against both resolutions. However, their dissenting votes represented just five shares out of 1,39,88,567 polled, indicating minimal opposition to the proposed changes. The scrutinizer’s report confirmed that all conditions under the Companies Act, 2013, and SEBI LODR regulations were fulfilled, validating the outcome.

What the Numbers Show

The near-total support from both promoter and public non-institutional shareholders underscores stable governance alignment at Indo Us Bio-Tech Limited. With promoters casting all their votes in favor and public retail investors showing a 99.9983% approval rate, the company demonstrates strong internal cohesion on critical board-level decisions. This level of consensus reduces future governance friction risks and supports smoother execution of strategic initiatives, including potential expansions in its agri-tech R&D capabilities.